Copied
 
 
2023, DKK
27.06.2024
Bruttoresultat

-2.194'

Primær drift

-2.194'

Årets resultat

-323'

Aktiver

520''

Kortfristede aktiver

520''

Egenkapital

-506''

Afkastningsgrad

-0 %

Soliditetsgrad

-97 %

Likviditetsgrad

51 %

Resultat
27.06.2024
Årsrapport
2023
27.06.2024
2022
29.06.2023
2021
27.06.2022
2020
04.06.2021
2019
03.06.2020
2018
31.05.2019
2017
13.06.2018
2016
14.06.2017
Nettoomsætning
Bruttoresultat-2.194.000-2.228.00013.495.00029.197.00020.517.0009.928.0006.533.000697.000
Resultat af primær drift-2.194.000-2.188.000-6.024.000-9.216.000-6.757.000-3.010.000-2.739.000-2.837.000
Indtægter af kapitalandele (tilknyttede og associerede) 00000000
Finansielle indtægter89.226.000-362.120.000-50.232.00046.754.0000000
Finansieringsomkostninger-76.697.000000-9.804.000-18.075.0007.991.000-559.000
Andre finansielle omkostninger00000000
Resultat før skat10.335.000-436.580.000-63.209.00037.538.000-16.561.000-21.085.0005.252.000-3.396.000
Resultat-323.000-440.671.000-63.209.00033.226.000-16.561.000-21.250.0005.271.000-2.828.000
Forslag til udbytte00000000
Aktiver
27.06.2024
Årsrapport
2023
27.06.2024
2022
29.06.2023
2021
27.06.2022
2020
04.06.2021
2019
03.06.2020
2018
31.05.2019
2017
13.06.2018
2016
14.06.2017
Kortfristede varebeholdninger00000000
Kortfristede tilgodehavender fra salg og tjenesteydelser 518.909.000000363.947.000213.094.000102.085.00018.784.000
Likvider644.0001.155.0001.750.000744.000981.0002.138.0001.522.0006.828.000
Kortfristede aktiver519.553.000395.503.000610.195.000493.874.000364.928.000215.232.000103.607.00025.612.000
Immaterielle aktiver og goodwill00000000
Finansielle anlægsaktiver00000000
Materielle aktiver00000000
Langfristede aktiver0072.272.00080.124.00080.090.00079.824.00079.574.00079.585.000
Aktiver519.553.000395.503.000682.467.000573.998.000445.019.000295.056.000183.181.000105.197.000
Aktiver
27.06.2024
Passiver
27.06.2024
Årsrapport
2023
27.06.2024
2022
29.06.2023
2021
27.06.2022
2020
04.06.2021
2019
03.06.2020
2018
31.05.2019
2017
13.06.2018
2016
14.06.2017
Forslag til udbytte00000000
Egenkapital-506.296.000-505.972.000-65.301.000-2.092.000-35.318.000-18.757.0002.493.000-2.778.000
Hensatte forpligtelser00000000
Langfristet gæld til banker00000000
Anden langfristet gæld2.273.0002.541.0002.203.0001.045.000000
Leverandører af varer og tjenesteydelser9.954.0006.609.0008.065.00011.059.0008.641.0008.336.00012.545.0008.125.000
Kortfristede forpligtelser1.023.159.000899.202.000745.227.000573.887.000479.292.000313.813.000180.688.000107.975.000
Gældsforpligtelser1.025.849.000901.475.000747.768.000576.090.000480.337.000313.813.000180.688.000107.975.000
Forpligtelser1.025.849.000901.475.000747.768.000576.090.000480.337.000313.813.000180.688.000107.975.000
Passiver519.553.000395.503.000682.467.000573.998.000445.019.000295.056.000183.181.000105.197.000
Passiver
27.06.2024
Nøgletal
27.06.2024
Årsrapport
2023
27.06.2024
2022
29.06.2023
2021
27.06.2022
2020
04.06.2021
2019
03.06.2020
2018
31.05.2019
2017
13.06.2018
2016
14.06.2017
Afkastningsgrad -0,4 %-0,6 %-0,9 %-1,6 %-1,5 %-1,0 %-1,5 %-2,7 %
Dækningsgrad Na.Na.Na.Na.Na.Na.Na.Na.
Resultatgrad Na.Na.Na.Na.Na.Na.Na.Na.
Varelagerets omsætningshastighed Na.Na.Na.Na.Na.Na.Na.Na.
Egenkapitals-forretning 0,1 %87,1 %96,8 %-1.588,2 %46,9 %113,3 %211,4 %101,8 %
Payout-ratio Na.Na.Na.Na.Na.Na.Na.Na.
Gældsdæknings-nøgletal -2,9 %Na.Na.Na.-68,9 %-16,7 %34,3 %-507,5 %
Soliditestgrad -97,4 %-127,9 %-9,6 %-0,4 %-7,9 %-6,4 %1,4 %-2,6 %
Likviditetsgrad 50,8 %44,0 %81,9 %86,1 %76,1 %68,6 %57,3 %23,7 %
Resultat
27.06.2024
Gæld
27.06.2024
Årsrapport
27.06.2024
Nyeste:01.01.2023- 31.12.2023(offentliggjort: 27.06.2024)
Information om virksomhedens regnskabsklasse:The annual report of Savara ApS for 2023 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B and the Accounting Standard on small enterprises, as well as provisions applying to reporting class C entities. The accounting policies applied are consistent with those of last year. The annual report for 2023 is presented in kDKK
Beretning
27.06.2024
Beskrivelse af usikkerhed ved indregning eller måling:Recognition and measurement uncertainties The preparation of the financial statements requires the making of estimates and judgments that affect the reporting of assets, liabilities and expenses. The estimates and judgments are reviewed on an ongoing basis. Estimates and judgments are based on historical results and on various other assumptions, which Savara believes to be reasonable under the circumstances. However, the actual results may differ significantly from the estimates. We believe that the accounting policies relating to receivables involve estimates or judgments by management that could materially affect the reported financial position and results.
Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen:Unusual matters The Company's financial position at 31 December 2023 and the results of its operations for the financial year ended 31 December 2023 are not affected by any unusual matters.
Oplysning om usædvanlige forhold:Savara is primarily exposed to exchange rate risks in the countries where Savara has its main activities i. e. the risks relate to the rise/fall in EUR and USD. It is Group policy not to actively conduct speculation in any financial risks and it is management’s strategy to seek to offset exchange-rate risks by matching positive cashflow, against costs in the same currencies.
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:The executive board has today discussed and approved the annual report of Savara ApS for the financial year 1 January - 31 December 2023.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Business review Savara ApS is a subsidiary of Savara Inc. , a U. S.-based emerging phamaceutical development company. Savara Inc (Texas/USA) became a public traded company on the NASDAQ Stock Exchange as of 28 April 2017. The main activity for Savara ApS is to be a holding company for the two subsidiaries - Drugrecure ApS and Pharmaorigin ApS.